Injection
Compounded Semaglutide injection
An ingredient may appear in several products. Start with the prescription name and the reason your clinician is considering it.

Compounded medicines are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before marketing. Package images are illustrations. Read the FDA’s guidance.
Match the name to the indication
Semaglutide is a GLP-1 receptor agonist. FDA-approved injectable products have specific uses and prescribing information. Ask which label applies and where you can read the patient information for that product.
Talk through the practical details
A product photograph cannot tell you what your pharmacy would dispense. Ask about the packaging, the supplies that come with it and who could demonstrate the actual device if one is prescribed.
Agree on a follow-up plan
Ask what changes the clinician would want to hear about before the next review and how to reach the team. If a compounded injection is discussed, ask for its source. Compounded drugs do not undergo FDA review for safety, effectiveness and quality before marketing.
Explore other injectables

Injection
Compounded Tirzepatide injection
Learn which product your clinician is discussing, why they are considering it and how they would review your progress.

Growth hormone–releasing peptide
Compounded Sermorelin injection
A separate hormone-related topic. Understanding why sermorelin came up is the first question to bring to a clinician.